Enavatuzumab is used for inhibiting tumor growth by targeting TWEAK receptor (TweakR); it suppresses the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo through direct TweakR signaling and antibody-dependent cell-mediated cytotoxicity (ADCC); it actively recruits and activates myeloid effector cells to kill tumor cells.